Diagnosis of ovine enzootic abortion using an indirect ELISA (rOMP91B iELISA) based on a recombinant protein fragment of the polymorphic outer membrane protein POMP91B of Chlamydophila abortus

Chlamydophila abortus is of major economic importance worldwide as one of the principal causes of abortion in sheep. Serological diagnosis of infection by the complement fixation test (CFT) is complicated by false positive reactions resulting from cross-reactive antibodies to Chlamydophila pecorum. To improve diagnosis an indirect enzyme-linked immunosorbent assay (iELISA) based on a recombinant protein fragment of the C. abortus polymorphic outer membrane protein POMP91B (rOMP91B iELISA) was assessed using a panel of 281 sera from experimentally and naturally infected sheep. The iELISA performed well, being more sensitive (84.2%) and specific (98.5%) than the CFT. Furthermore, the iELISA was better at differentiating C. abortus- from C. pecorum-infected animals. The new rOMP91B iELISA test will prove a valuable tool for the routine serodiagnosis of C. abortus infection.     

凋亡素融合蛋白的可溶性表达及活性分析

目的:构建PET-28a-SPA原核表达载体,在大肠杆菌BL21(DE3)中实现其高效可溶性表达,测定对肿瘤细胞的凋亡效果。方法:本实验在获得凋亡蛋白融合基因的基础上,成功地构建了重组表达质粒PET-28a-SPA,将阳性重组质粒转化表达受体菌BL21(DE3)感受态细胞中,经IPTG诱导表达,表达产物经聚丙烯酰胺凝胶电泳检测和Western blot检测,并采用MTT法检测其对肿瘤细胞的增殖抑制。结果:表达产物经聚丙烯酰胺凝胶电泳检测,凋亡蛋白融合基因获得高效表达,软件分析表明表达蛋白占菌体蛋白20%左右。上清表达量约为10%。上清蛋白经纯化后,Western blot结果显示,利用凋亡蛋白单克隆抗体可以很好地和所表达的蛋白带特异性结合,并且对A549肺癌细胞及Hela细胞具有一定的凋亡作用。结论:所获凋亡蛋白以高效胞质可溶形式表达,为其研制有效的肿瘤免疫治疗靶向药物提供一定的基础。     

Expression, purification, and characterization of recombinant purine nucleoside phosphorylase from Escherichia coli.

Recombinant purine nucleoside phosphorylase (PNPase) from Escherichia coli was prepared in high yield in order to facilitate its use in coupled assays to measure the kinetics of phosphate-liberating enzymes. The E. coli enzyme was overexpressed in E. coli by inserting the genomic fragment containing the deoD gene downstream of the isopropyl beta-d-thiogalactoside-inducible promotor of pSE380 expression vector. The recombinant protein was purified to approximately 90% homogeneity and with a yield of approximately 9000 units of activity/L of culture, using an efficient one-column procedure. A continuous spectrophotometric assay coupling P(i) release to the phosphorolysis of the nucleoside analogue 7-methylinosine (m(7)Ino) was recently described. Here, we report the steady-state kinetic parameters of the recombinant E. coli PNPase catalyzed reaction with m(7)Ino and P(i) as substrates and compare these parameters with those of a bacterial PNPase commercially available for use in coupled assays. Under the assay conditions described, the recombinant E. coli protein is active at higher pH values and is stable up to a temperature of approximately 55 degrees C and following multiple freeze-thaw cycles. It is activated by high ionic strength but loses some activity following dialysis or concentration under pressure. Finally, a new procedure for the synthesis of m(7)Ino from inosine is described which is safe and cost effective, making the use of this methylated nucleoside in PNPase-coupled P(i) assays more attractive.     

HIV-1 CN54 Pol P51抗原高效表达、纯化、复性及在抗体检测中的应用

为获得可溶性高纯度HIV-1中国株CN54PolP51抗原,将携带CN54polp51基因的重组质粒pTHioHisA51转化大肠杆菌BL21codonplus-RIL,用IPTG进行诱导表达。用Chelating SepharoseFF-Ni亲和层析柱及DEAE Sepharose Fast Flow阴离子交换层析柱纯化目的蛋白,采用透析复性法得到可溶性抗原,Western blotting检测目的蛋白。用纯化的P51抗原蛋白标记辣根过氧化物酶及包被酶标板进行双抗原夹心法ELISA检测。结果显示P51以包涵体的形式表达,表达量占菌体总蛋白的50%,经两步层析和透析复性,目的蛋白纯度大于95%。Western blotting和双抗原夹心法ELISA检测均显示了良好的灵敏度和特异性。本研究可以为HIV-1疫苗研究和开发检测试剂提供支持。     

High-sensitivity hybridization assay for quantitation of residual E. coli DNA

Impurity assays for recombinant protein therapeutics are essential to ensure batch-to-batch consistency and to meet the FDA's criteria for a well-characterized biopharmaceutical. For determination of residual host cell DNA, membrane hybridization assays utilizing radiolabeled DNA probes prepared from the host cell's genomic DNA have traditionally been used for products derivedfrom bacterial expression systems to obtain the required low picogram sensitivity. Nonradioactive methods, while desirable to eliminate radioactive waste disposal and safety issues, typically suffer from poor sensitivity and high backgrounds. We report the development of a suitably sensitive, nonradioactive assay to quantitate residual E. coli DNA levels in purified protein drugs by means of a slot-blot hybridization method. The assay utilizes digoxigenin-labeled E. coli DNA probes and SuperSignal chemiluminescent substrate. The optimized chemiluminescent hybridization assay has both low background and high sensitivity, allowing routine detection of 2.5 pg E. coli DNA. The method can be tailored for detection/quantitation of DNA contamination in recombinant protein products expressed in E. coli or other bacterial expression systems.     

alpha-Carboxyl-linked glutamates in the folylpolyglutamates of Escherichia coli

Folate cofactors in most cells contain polyglutamate side chains, which since the late 1940s have been assumed to be linked via their gamma-COOH groups. We report here an investigation of the structure of the polyglutamate chain attached to the folates of Escherichia coli. Folates were extracted from E. coli grown with [7-14C] p-aminobenzoate and cleaved to p-aminobenzoyl polyglutamates of varying chain lengths (pAB(Glu)n) by the method of Foo et al. (Foo, S. K., Cichowicz, D. J., and Shane, B. (1980) Anal. Biochem. 107, 109-115). The pAB(Glu)n derived from E. coli did not co-chromatograph with chemically synthesized pAB(gamma-Glu)n-Glu on several high performance liquid chromatography (HPLC) systems, except for the triglutamate which did elute with pAB(gamma-Glu)2-Glu. E. coli-derived pAB(Glu)3-8 were purified by HPLC on C18 columns eluted with acetonitrile/trifluoroacetic acid, and the structures were determined through mass spectrometry, chiral amino acid analysis, and peptidase digestion experiments. Molecular weight determinations on the methyl ester derivatives of E. coli-derived pAB(Glu)n by liquid secondary ion mass spectrometry and sequence analysis using collision-activated dissociation on a tandem mass spectrometer confirmed the structures as pAB(Glu)3-8. Chiral HPLC of hydrolyzed and dansylated E. coli-derived materials, on a beta-cyclodextrin column, identified the glutamate as the L-enantiomer. pAB(Glu)n were digested with carboxypeptidase Y, which specifically cleaved glutamates linked at their alpha-carboxyls; E. coli-derived pAB(Glu)4-8 (but not synthetic pAB(gamma-Glu1-6-Glu) were sequentially digested to pAB(gamma-Glu)2-Glu. Thus, in E. coli folylpolyglutamates, glutamate residues 4-8 were each linked to the polyglutamate chain at the alpha-carboxyl of the preceding glutamate.     

High-level expression, purification and pro-apoptosis activity of HIV-TAT-survivin (T34A) mutant to cancer cells in vitro

Survivin, a novel member of the IAP family, was observed to express in the most common human cancers. Anti-cancer therapy targeting survivin had drawn considerable attention. This study focused on high-level expression of recombinant protein TAT-survivin (T34A) mutant in E. coli, purification and bioactivity of pro-apoptosis to various cell lines in vitro. The cDNA encoding survivin was cloned by RT-PCR from breast cancer cell lines B-cap37. After PCR site-directed mutagenesis and construction of expression vector pRSET-B-TAT-survivin (T34A), targeted TAT-survivin (T34A) protein was expressed highly in E. coli BL21 (DE3) by 0.5mM IPTG induction and its yield could reach 650 mg/l in fermentation culture. The fusion protein in a form of inclusion body was then solubilized, refolded and purified to a purity of 98% by cation exchange chromatography and size-exclusion chromatography. Four hundred and eighty milligrams protein of interest was obtained in per liter fermentation culture. This showed that the efficient procedures of large-scale expression and purification were successful for the mass production of the recombinant protein. Pro-apoptosis effects of target protein on four cancer cell lines and one normal cell line from human were confirmed by the change of morphology, and pro-apoptosis activity was evaluated by MTT, fluorescent staining of nuclei and flow cytometry assay. Results indicated that B-cap37 and SW1990 were very sensitive to TAT-survivin (T34A) protein. This finding revealed the recombinant protein was promising as an anti-cancer drug.     

Molecular characterization of American cockroach tropomyosin (Periplaneta americana allergen 7), a cross-reactive allergen

Inhalation of allergens produced by the American cockroach (Periplaneta americana) induces IgE Ab production and the development of asthma in genetically predisposed individuals. The cloning and expression in Escherichia coli of P. americana tropomyosin allergen have been achieved. The protein shares high homology with other arthropod tropomyosins (80% identity) but less homology with vertebrate ones (50% identity). The recombinant allergen was produced in E. coli as a nonfusion protein with a yield of 9 mg/l of bacterial culture. Both natural and recombinant tropomyosins were purified by isoelectric precipitation. P. americana allergen 1 (Per a 1) and Per a 7 (tropomyosin) are to date the only cross-reacting allergens found in cockroaches. ELISA and Western blot inhibition experiments, using natural and recombinant purified tropomyosins from shrimp and cockroach, showed that tropomyosin induced cross-reactivity of IgE from patients allergic to these allergens, suggesting that this molecule could be a common allergen among invertebrates.     

HIV P66蛋白的表达、纯化及活性检测

此研究的目的是体外表达HIV-1逆转录酶P66亚单位蛋白,并得到纯度较高且具有活性的重组蛋白。首先通过PCR方法从含HIV-1 HXB2标准株全基因的质粒中扩增出全长p66基因,插入表达载体pTWIN1,构建pTWIN-p66质粒。再将该质粒转化到表达菌BL21,在IPTG诱导下表达P66蛋白。表达产物经几丁质柱一步纯化后得到P66蛋白纯品。纯化的P66蛋白分别催化B95-8细胞总RNA、RT试剂盒中对照RNA进行逆转录;同时以试剂盒中的M-MLV RT为对照进行相同的逆转录,PCR后电泳比较活性。结果显示我们构建的pTWIN-p66质粒在IPTG诱导下在原核细胞中P66亚单位蛋白表达量较高,经一步纯化后蛋白凝胶扫描纯度达88%,并具有较好的逆转录活性。与M-MLV RT体外活性比较,两者活性相当。该研究为进一步开发国产HIV确证诊断试剂及抗AIDS药物的研究打下了初步基础。     

大肠杆菌脑微血管内皮细胞侵袭基因ibeB的编码产物为外膜蛋白前体

为进一步探讨大肠杆菌脑微血管内皮细胞侵袭基因ibeB的生物学特性 ,将ibeB基因克隆到pET2 8a(+)载体 ,以E .coliBL2 1 (DE3)为宿主菌 ,经IPTG诱导后 ,通过Ni2 + NTA树脂提纯IbeB蛋白 .SDS PAGE确定纯化蛋白的分子量 ;应用无蛋白酶的体外转录和翻译系统进一步鉴定ibeB基因表达蛋白的分子量 ;通过 [3 5S]Met标记的体内T7表达体系并结合膜蛋白分离技术定位IbeB蛋白在细菌中的亚细胞分布 ;利用细菌侵袭实验分析IbeB蛋白抗体对E .coliK1侵袭人脑微血管内皮细胞的封闭作用 .结果发现 ,ibeB基因的重组蛋白表达纯化产物呈现出 5 0kD和 34kD两种分子量大小 ,5 0kD存在于表达细菌的可溶性部分 ,而 34kD则存在于包涵体中 ;体外翻译实验也显示出较弱的 5 0kD和较浓的 34kD两个蛋白带 ;体内T7表达体系实验显示 34kD的IbeB成熟蛋白定位于E .coli的外膜 ;抗 34kDIbeB蛋白抗体能封闭E .coli对人脑微血管内皮细胞的侵袭 .这些结果提示 ,大肠杆菌脑微血管内皮细胞侵袭基因ibeB的编码产物为 5 0kD的外膜蛋白前体 ,该前体可通过分子内剪接形成成熟的 34kDIbeB蛋白     

Expression and purification of the recombinant enteropathogenic Escherichia coli vaccine candidates BfpA and EspB

BfpA, the structural repeating protein subunit A of the bundle-forming pilus and EspB, a type-III-secreted pore-forming protein of enteropathogenic Escherichia coli (EPEC), both virulence factors central for EPEC pathogenesis, were overexpressed in E. coli DH5alpha and M15 laboratory strains, respectively, using the pQE-30 cloning expression system, as chimeric fusions to a NH(2)-terminal histidine hexapeptide (His(6)-tag) sequence. After isopropyl beta-d-thiogalactoside induction, the expression levels achieved were 11 and 40% of total soluble protein for BfpA and EspB, respectively. The His(6)-tagged recombinant proteins were purified (up to 98% homogeneity) by Ni-agarose affinity chromatography and produced yields varying from 0.65 to 3.1 mg of recombinant protein per gram of wet weight cells. The immunogenicity and antigenicity of the final products were tested in rabbits and using fecal specimens obtained from children suffering from acute watery diarrhea, respectively. The recombinant products correspond to antigenically authentic protein standards, useful in future epidemiological and neonatal vaccinology studies.     

以重组P-gp为抗原建立检测MDR 1抗体间接ELISA方法的研究

目的:构建MDR 1基因原核表达质粒,表达P-gp重组蛋白,建立检测MDR1抗体的间接ELISA方法。方法:利用重组PCR技术扩增MDR 1基因的1kb片段,克隆至pET-28b（＋）中,构建原核表达质粒pETP-gp,转染感受态菌BL21（DE3）和BL21（DE3）plyss;以E.coli高效表达的P-gp基因主要抗原编码区重组蛋白为抗原,以HRP标记的兔抗人IgG为二抗,建立间接ELISA检测方法。结果:正确构建了pETP-gp原核表达质粒,并可在E.coli中高效表达,表达蛋白可用作检测MDR 1抗体ELISA抗原。结论:成功表达出重组蛋白P-gp,建立了检测MDR 1抗体的间接ELISA方法。     

鸭源致病性大肠杆菌Ⅰ型菌毛pilA基因的原核表达及重组蛋白对强毒攻击的免疫保护作用

根据GenBank中人源大肠杆菌pilA基因序列,用OLIGO6.0设计PCR引物,从鸭源致病性大肠杆菌GH1.2中扩增到pilA基因并将其克隆至pMD18-T载体,经PCR、酶切和DNA测序鉴定后,将鸭源致病性大肠杆菌pilA基因正向插入原核表达载体pET-32a( )的BamHⅠ和HindⅢ位点间,成功构建了重组表达质粒pET-32a-pilA。重组表达质粒pET-32a-pilA转化表达宿主菌BL21(DE3),用IPTG诱导,表达出了大小约为36kD的pilA重组蛋白。表达产物用镍柱亲和层析纯化,与等量弗氏佐剂混合制备pilA重组蛋白疫苗,分别在1日龄、8日龄时两次对雏鸭进行免疫,二免后2周测定鸭血清中的ELISA抗体效价,并以109PFU同源菌株GH1.2攻毒,根据攻毒后鸭的死亡率、E.coli分离率和各组织器官的病变等级来判定pilA重组蛋白的免疫保护效果。结果pilA重组蛋白免疫鸭的血清中ELISA抗体效价为1∶12800,全菌灭活苗免疫组的血清ELISA抗体效价为1∶200;同源菌株攻毒后,pilA重组蛋白免疫保护组鸭的死亡率、E.coli分离率和各组织器官的病变程度均比攻毒对照组下降且差异显著或极显著,与全菌灭活苗免组比较差异不显著。表明pilA重组蛋白对同源菌株GH1.2的感染具有一定的保护效果。     

Development of a fed-batch process for the production of the cytochrome P450 monooxygenase CYP102A1 from Bacillus megaterium in E. coli

A fed-batch process utilizing a pET-based expression system (pET28a+ derivative) and E. coli BL21(DE3) as production strain for the heterologous expression of recombinant cytochrome P450 monooxygenase CYP102A1 from Bacillus megaterium was developed. In a first step the expression was optimized during a series of flask experiments testing several parameters for their influence on the expression level, activity and solubility of the recombinant protein. The optimal process parameters found in the flask experiments were transferred to a cultivation process in a 5l (operating volume) bioreactor with a special focus on the feeding strategy and the aeration during expression. Glycerol feeding proved to be superior over glucose as carbon source since the formation of larger amounts of acetate was prevented. Expression levels exceeding 12,500nmoll(-1), corresponding to approximately 1.5gl(-1) of product in culture medium ( approximately 11% of CDW) could be demonstrated. The P450 enzyme showed high activity and high solubility. The findings now can be transferred to other enzyme variants and different P450 monooxygenases to increase production of recombinant proteins.     

可溶性HLA-A*0203-BSP原核表达载体的构建及其在大肠杆菌中的高效表达

目的：构建HLA-A*0203重链胞外域羧基端融合生物素化酶BirA底物肽(BSP)的融合蛋白（HLA-A*0203-BSP）的原核表达载体并在大肠杆菌中进行表达。方法：以RT-PCR方法从HLA-A2+ 供者外周血单个核细胞(PBMC)中克隆HLA-A*0203重链基因的cDNA并测序鉴定,然后以PCR方法构建HLA-A*0203-BSP的原核表达载体,在大肠杆菌BL21(DE3)菌株中诱导表达并以免疫印迹鉴定。结果：DNA测序显示,从3名HLA-A2+ 供者PBMC中克隆的cDNA中,只有从供者2获得编码HLA-A*0203重链基因的cDNA。将编码重链胞外域1-276的序列和编码BSP的序列融合,构建HLA-A*0203-BSP融合蛋白的原核表达载体并经测序验证。该融合蛋白在BL21(ED3)中获得高效表达,约占菌体总蛋白的30％;产物相对分子质量约为34 kD,与理论大小一致。Western印迹分析显示融合蛋白完全存在于包涵体中。结论：成功克隆HLA-A*0203重链基因的cDNA,构建HLA-A*0203-BSP融合蛋白的原核表达载体,并在大肠杆菌中获得高效表达,为制备HLA-A*0203四聚体打下基础。     

重组HIV-TATm-Survivin(T34A)蛋白制备及其促癌细胞凋亡活性研究

从人乳腺癌细胞系B-Cap-37中克隆出Survivin的cDNA,并对其中编码34位Thr的密码子定点突变为Ala的密码子后,经一系列基因操作方法将天然HIV-TAT转导肽的突变体基因HIV-TATm引入Survivin(T34A)基因的5′端,正确构建了表达载体pRSET-B-HIV-TATm-Survivin(T34A),经转化E.coliBL21(DE3)后诱导表达,目的蛋白质以包涵体形式表达,占菌体总蛋白的45%。经3.7L发酵罐分批发酵可收获650mg/L的包涵体,经阳离子交换、凝胶层析分离和柱上复性与透析,得到纯度达96%以上的可溶性目的蛋白HIV-TATm-Survivin(T34A)。目的蛋白对人乳腺癌细胞B-Cap-37、人胰腺癌细胞SW1990和人肝癌细胞SSMC-7721作用4h后有在细胞形态上呈现出显著的凋亡特征,而对人宫颈癌细胞系Hela不敏感,对正常的人内皮细胞系EVC-304未见明显影响。作用24h时MTT法检测显示,120μg/mL目的蛋白对SW1990、B-Cap-37、SSMC-7721和Hela细胞的抑制率分别达到89%、63%、59.5%和39%,且具有剂量依赖性。对最为敏感的SW1990和B-Cap-37以每孔60μg/mL终浓度的目的蛋白作用48h的流式细胞技术检测发现,凋亡率分别为25.6%和19.3%,与对照相比,实验组细胞出现明显的凋亡峰,细胞周期的分布发生明显的变化,65%以上的癌细胞被阻滞于G1期。体外实验结果显示重组目的蛋白具有较强的抑制癌细胞增殖和促进凋亡作用,预示着良好的抗癌前景。     

大肠杆菌ptsG基因敲除及其缺陷株生长特性研究

在大肠杆菌磷酸转移酶系统中,葡萄糖主要由ptsG基因编码的酶ⅡCB^Glc转运入细胞。利用代谢工程技术构建ptsG基因缺陷株,有望降低葡萄糖的摄取速率,减少乙酸累积,促进菌体生长。运用PCR技术,扩增出两翼与ptsG基因上下游序列同源,中间为氯霉素抗性基因的DNA片段。经电转化,将外源DNA片段分别转入Escherichia coli DH5a、JM109中。在Red重组酶的作用下,外源DNA片段与染色体上同源区域重组,将基因ptsG敲除,构建ptsG基因缺陷株：DH5αP,JM109P。在LB培养基中,ptsG基因缺陷株的生长状况与亲株无明显差异。在含有葡萄糖的LB培养基中,DH5αP、JM109P的最高菌密度分别是对照菌株DH5α,JM109的3．47倍和4．25倍,ptsG基因缺陷株对葡萄糖的摄入量也明显高于对照菌株。重组蛋白肿瘤坏死因子(TNF)在DH5αP、JM109P中的表达量分别占全菌蛋白的24．3％、20．8％,A600分别为8．28、7．62,TNF在缺陷株中单位体积的表达量明显高于对照菌株。以上结果说明,大肠杆菌ptsG基因缺陷株具有良好的生长能力和表达外源蛋白的能力,在大肠杆菌高密度发酵研究方面具有良好的应用前景。